Panaji Journal

Non Muscle Invasive Bladder Cancer Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | UroGen Pharma, Pfizer, Roche, CG Oncology, enGene

 Breaking News
  • No posts were found

Non Muscle Invasive Bladder Cancer Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | UroGen Pharma, Pfizer, Roche, CG Oncology, enGene

November 28
14:31 2023
Non Muscle Invasive Bladder Cancer Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | UroGen Pharma, Pfizer, Roche, CG Oncology, enGene
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Non Muscle Invasive Bladder Cancer pipeline constitutes 25+ key companies continuously working towards developing 30+ Non Muscle Invasive Bladder Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Non Muscle Invasive Bladder Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Non Muscle Invasive Bladder Cancer Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Non Muscle Invasive Bladder Cancer Market.

 

Some of the key takeaways from the Non Muscle Invasive Bladder Cancer Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Non Muscle Invasive Bladder Cancer treatment therapies with a considerable amount of success over the years. 
  • Non Muscle Invasive Bladder Cancer companies working in the treatment market are Tollys, Vaxiion Therapeutics, Incyte Corporation, Janssen Pharmaceuticals, Theralase Technologies, Pfizer, BristolMyers Squibb, Asieris Pharmaceutical, UroGen Pharma, Pfizer, Roche, CG Oncology, ImmunityBio, enGene, SURGE Therapeutics, Aura Biosciences, UroGen Pharma Ltd., FKD Therapies Oy, ImmunityBio, Inc., Protara Therapeutics, Janssen Research & Development, LLC, Tyra Biosciences, Inc, and others, are developing therapies for the Non Muscle Invasive Bladder Cancer treatment 
  • Emerging Non Muscle Invasive Bladder Cancer therapies in the different phases of clinical trials are- TL-532, VAX 014, Pemigatinib, Erdafitinib, TLD 1433, PF-06801591, Nivolumab, APL-1202, UGN-102, Sasanlimab (PF-06801591), TECENTRIQ, CG0070, N-803, EG-70, STM-416, AU-011, UGN-102, ADSTILADRIN, BCG+N-803, TARA-002, TAR-200, TYRA-300, and others are expected to have a significant impact on the Non Muscle Invasive Bladder Cancer market in the coming years.  
  • In December 2022, The US FDA granted approval to ADSTILADRIN (nadofaragene firadenovec-vncg), a gene therapy utilizing a non-replicating adenoviral vector. It is designated for treating adults with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) that includes carcinoma in situ (CIS) with or without papillary tumors.
  • In January 2022, Asieris Pharmaceuticals announced that the world’s first patient dose has been administered in U.S. forits oral APL-1202 in combination with BeiGene’s tislelizumab as neoadjuvant therapy in patients with muscle invasivebladder cancer (MIBC)
  • In October 2021, Asieris Pharmaceuticals initiated a Multi-center, Randomized, Open-label, Parallel controlled Phase 3 Clinical Trial to Evaluate the Clinical Safety and Efficacy of APL-1202 as a Single-agent Oral TreatmentVersus Intravesical Instillation of Epirubicin Hydrochloride in naïve Intermediate-risk Non-muscle Invasive Bladder Cancer (NMIBC) Patients. 

 

Non Muscle Invasive Bladder Cancer Overview

Cancer in the tissue lining the bladder’s inner wall is known as non-muscle invasive bladder cancer (NMIBC). The muscle of the bladder is not used. The sixth most frequent cancer in the US is bladder cancer. In 2020, around 81,000 Americans will receive a bladder cancer diagnosis.

 

Get a Free Sample PDF Report to know more about Non Muscle Invasive Bladder Cancer Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/non-muscle-invasive-bladder-cancer-pipeline-insight

 

Emerging Non Muscle Invasive Bladder Cancer Drugs Under Different Phases of Clinical Development Include:

  • TL-532: Tollys
  • VAX 014: Vaxiion Therapeutics
  • Pemigatinib: Incyte Corporation
  • Erdafitinib: Janssen Pharmaceuticals
  • TLD 1433: Theralase Technologies
  • PF-06801591: Pfizer
  • Nivolumab: BristolMyers Squibb
  • APL-1202: Asieris Pharmaceuticals

 

Non Muscle Invasive Bladder Cancer Route of Administration

Non Muscle Invasive Bladder Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical

 

Non Muscle Invasive Bladder Cancer Molecule Type

Non Muscle Invasive Bladder Cancer Products have been categorized under various Molecule types, such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

 

Non Muscle Invasive Bladder Cancer Pipeline Therapeutics Assessment

  • Non Muscle Invasive Bladder Cancer Assessment by Product Type
  • Non Muscle Invasive Bladder Cancer By Stage and Product Type
  • Non Muscle Invasive Bladder Cancer Assessment by Route of Administration
  • Non Muscle Invasive Bladder Cancer By Stage and Route of Administration
  • Non Muscle Invasive Bladder Cancer Assessment by Molecule Type
  • Non Muscle Invasive Bladder Cancer by Stage and Molecule Type

 

DelveInsight’s Non Muscle Invasive Bladder Cancer Report covers around 30+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Non Muscle Invasive Bladder Cancer product details are provided in the report. Download the Non Muscle Invasive Bladder Cancer pipeline report to learn more about the emerging Non Muscle Invasive Bladder Cancer therapies

 

Some of the key companies in the Non Muscle Invasive Bladder Cancer Therapeutics Market include:

Key companies developing therapies for Non Muscle Invasive Bladder Cancer are – UroGen Pharma, Pfizer, Roche, CG Oncology, ImmunityBio, Theralase, enGene, SURGE Therapeutics, Aura Biosciences, UroGen Pharma Ltd., FKD Therapies Oy, ImmunityBio, Inc., Protara Therapeutics, Janssen Research & Development, LLC, Tyra Biosciences, Inc, and others.

 

Non Muscle Invasive Bladder Cancer Pipeline Analysis:

The Non Muscle Invasive Bladder Cancer pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Non Muscle Invasive Bladder Cancer with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non Muscle Invasive Bladder Cancer Treatment.
  • Non Muscle Invasive Bladder Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Non Muscle Invasive Bladder Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non Muscle Invasive Bladder Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Non Muscle Invasive Bladder Cancer drugs and therapies

 

Non Muscle Invasive Bladder Cancer Pipeline Market Drivers

  • Increase in the number of patients suffering from non-muscle invasive bladder cancer. Approximately 70-75% bladder cancers are non-muscle invasive bladder cancer (NMIBC), development of novel therapies and favorable government policies are some of the important factors that are fueling the Non Muscle Invasive Bladder Cancer Market.

 

Non Muscle Invasive Bladder Cancer Pipeline Market Barriers 

  • However, identifying the patient population with specific mutations for targeted therapy regimens, lack of awareness about the advanced cancer therapies and other factors are creating obstacles in the Non Muscle Invasive Bladder Cancer Market growth.

 

Scope of Non Muscle Invasive Bladder Cancer Pipeline Drug Insight    

  • Coverage: Global
  • Key Non Muscle Invasive Bladder Cancer Companies: Tollys, Vaxiion Therapeutics, Incyte Corporation, Janssen Pharmaceuticals, Theralase Technologies, Pfizer, BristolMyers Squibb, Asieris Pharmaceutical, UroGen Pharma, Pfizer, Roche, CG Oncology, ImmunityBio, enGene, SURGE Therapeutics, Aura Biosciences, UroGen Pharma Ltd., FKD Therapies Oy, ImmunityBio, Inc., Protara Therapeutics, Janssen Research & Development, LLC, Tyra Biosciences, Inc, and others
  • Key Non Muscle Invasive Bladder Cancer Therapies: TL-532, VAX 014, Pemigatinib, Erdafitinib, TLD 1433, PF-06801591, Nivolumab, APL-1202, UGN-102, Sasanlimab (PF-06801591), TECENTRIQ, CG0070, N-803, EG-70, STM-416, AU-011, UGN-102, ADSTILADRIN, BCG+N-803, TARA-002, TAR-200, TYRA-300, and others
  • Non Muscle Invasive Bladder Cancer Therapeutic Assessment: Non Muscle Invasive Bladder Cancer current marketed and Non Muscle Invasive Bladder Cancer emerging therapies
  • Non Muscle Invasive Bladder Cancer Market Dynamics: Non Muscle Invasive Bladder Cancer market drivers and Non Muscle Invasive Bladder Cancer market barriers 

 

Request for Sample PDF Report for Non Muscle Invasive Bladder Cancer Pipeline Assessment and clinical trials

 

Table of Contents

1. Non Muscle Invasive Bladder Cancer Report Introduction

2. Non Muscle Invasive Bladder Cancer Executive Summary

3. Non Muscle Invasive Bladder Cancer Overview

4. Non Muscle Invasive Bladder Cancer- Analytical Perspective In-depth Commercial Assessment

5. Non Muscle Invasive Bladder Cancer Pipeline Therapeutics

6. Non Muscle Invasive Bladder Cancer Late Stage Products (Phase II/III)

7. Non Muscle Invasive Bladder Cancer Mid Stage Products (Phase II)

8. Non Muscle Invasive Bladder Cancer Early Stage Products (Phase I)

9. Non Muscle Invasive Bladder Cancer Preclinical Stage Products

10. Non Muscle Invasive Bladder Cancer Therapeutics Assessment

11. Non Muscle Invasive Bladder Cancer Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Non Muscle Invasive Bladder Cancer Key Companies

14. Non Muscle Invasive Bladder Cancer Key Products

15. Non Muscle Invasive Bladder Cancer Unmet Needs

16 . Non Muscle Invasive Bladder Cancer Market Drivers and Barriers

17. Non Muscle Invasive Bladder Cancer Future Perspectives and Conclusion

18. Non Muscle Invasive Bladder Cancer Analyst Views

19. Appendix

20. About DelveInsight

 

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services